U.S. Markets closed

Radient Pharmaceuticals Announces Results for U.S. Clinical Trial of Onko-Sure(R) for Colorectal Cancer

TUSTIN, CA--(Marketwire - 04/27/11) - Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC - News) announced today the results of its analysis of data from the U.S. clinical trial conducted in collaboration with a well-recognized, large third-party not-for-profit group practice and its affiliates for RPC's Onko-Sure® in vitro diagnostic (IVD) cancer test.Based on the final trial analysis, it has been determined that Onko-Sure® (DR-70) is a useful tool when combined with Carcinoembryonic Antigen (CEA) in detecting colorectal cancer (CRC) in all stages, and specifically, in early Stages (stages I and II) where early diagnosis and treatment can lead to better patient prognosis. Additionally, the study demonstrated RPC's Onko-Sure® IVD cancer test can be up to 17% more effective in detecting CRC in Stages I and II over Carcinoembryonic Antigen (CEA). Furthermore, the study also showed when Onko-Sure® is combined with CEA, the sensitivity of the combined tests delivers additional increased sensitivity as opposed to using CEA alone.RPC plans to disseminate these results in a peer-reviewed journal, either independently or with other third party healthcare organizations. Additionally, RPC plans to present these results to physicians at international oncology conferences and scientific meetings.RPC's Chairman and CEO Douglas MacLellan commented, "We are extremely pleased with the final data set analysis of this trial and look forward to broadly disseminating the findings. This is a significant milestone for Radient Pharmaceuticals, our dedicated staff, loyal shareholders and cancer patients, and for the future commercialization of this product."Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.RPC Contact Information:
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.